Icon Plc (ICLR) Stock Price
ICLRStock
$170.18−9.70%52W
Market Cap$13.13B
P/E57.25x
PEG Ratio0.53
Div yield—
Beta1.22
ICLR Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)40.62%
Price vs S&P 500 (4W)1.70%
PEG Ratio0.53
VGM Score49.94
P/E Ratio (Annual)57.25x
ICLR Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | $2.52 | $2.56 | +1.70%(+$0.04) | |
| Q1 2026 | $2.43 | $2.50 | +3.05%(+$0.07) | |
| Q4 2025 | $3.11 | $2.52 | -18.87%(-$0.59) | |
| Q3 2025 | $3.28 | $3.31 | +1.04%(+$0.03) | |
| Q2 2025 | $3.18 | $3.26 | +2.40%(+$0.08) |
ICLR Analyst Recommendations
Jun 2026
Jul 2026
Aug 2026
Sep 2026
3.75
3.83
3.83
3.83
Industry Peers — R&D — Physical Sciences(17)
| Symbol | Value Score | Growth Score | Momentum Score | P/E Ratio (Annual) | ROE (TTM) | Revenue Growth (5Y) | Indicated Dividend Yield (Annual) | Price |
|---|---|---|---|---|---|---|---|---|
ICLRIcon Plc | C | C | B | 57.3x | 0.8% | 24.1% | — | $170.18 |
| IQVIQVIA Holdings Inc. | D | C | A | 32.3x | 21.9% | 7.5% | — | $266.90 |
| INCYIncyte Genomics Inc | C | B | B | 17.8x | 29.6% | 14.0% | — | $113.07 |
| MEDPMedpace Holdings, Inc. Common Stock | F | B | B | 38.3x | 110.2% | 22.3% | — | $618.47 |
| CRLCharles River Laboratories International, Inc. | F | D | A | — | -7.7% | 6.5% | — | $300.15 |
| ABSIAbsci Corporation Common Stock | F | F | B | — | -59.2% | -10.1% | — | $8.25 |
| OABIOmniAb, Inc. Common Stock | F | B | A | — | -16.6% | -4.3% | — | $4.59 |
| NRCNRC Health Common Stock | D | D | B | 38.4x | 48.5% | 0.6% | 1.2% | $20.15 |
| MXCTMaxCyte, Inc. Common Stock | C | D | B | — | -21.0% | 4.8% | — | $1.30 |
| IBACIB Acquisition Corp. Common Stock | — | D | C | 15.9x | -3.7% | — | — | $10.86 |
| ONMDOneMedNet Corp Class A Common Stock | D | A | D | — | -6.8% | — | — | $4.51 |
About Icon Plc
Icon is a global contract research organization providing clinical trial and drug development services to pharmaceutical, biotechnology, and medical device companies. The company derives the majority of its revenue from clinical research operations, complemented by laboratory and imaging services. Icon is headquartered in Dublin, Ireland.